Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YCH3971: sourced facts only. name: "Among these compounds, YCH3971 exhibited potent inhibiting activity against PARP1 with an IC50 of 7.52 nM, showing a remarkable subtype selectivity compared with PARP2 (>1000-fold)." [PMID:41672027]; target: "Among these compounds, YCH3971 exhibited potent inhibiting activity against PARP1 with an IC50 of 7.52 nM, showing a remarkable subtype selectivity compared with PARP2 (>1000-fold)." [PMID:41672027]; developer: "State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China." [PMID:41672027]; stage: "Also, YCH3971 possessed a strong antiproliferative activity on BRCA mutant MDA-MB-436 cells with an IC50 of 2.10 nM." [PMID:41672027]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on YCH3971.